Ginkgo Bioworks will go public through a merger with a blank-check company led by former Hollywood executives Harry Sloan and Jeff Sagansky, in a deal that values the biotech company at $15 billion, the companies said on Tuesday, reports Reuters. The deal with Soaring Eagle Acquisition Corp is expected to fetch $2.5 billion in proceeds for the combined entity, the companies said. Baillie Gifford, Putnam Investments and accounts advised by ARK Investment Management have agreed to invest $775 million in the deal.
Biotech firm Ginkgo to merge with SPAC in $15b deal
FE Team | Published: May 11, 2021 22:10:06
Biotech firm Ginkgo to merge with SPAC in $15b deal
Share if you like